Evidence map›Paper›PMID 33347987›Full record

ReviewFree radical biology & medicine2021

The role of NO in COVID-19 and potential therapeutic strategies.

Wanyi Fang, Jingrui Jiang, Lei Su, Tong Shu, Huan Liu, Shenghan Lai, Reza A Ghiladi, Jun Wang

2 registry-linked trialsOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Free radical biology & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
2.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04290871 phase2withdrawnnot on this mapstarted 2023, after this paper: background citation

Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.

TypeinterventionalSponsorXijing HospitalRan2023 to 2024Enrolled0ConditionsCoronavirus Covid-19 Infection Variant Omicron, SARS (Severe Acute Respiratory Syndrome)ArmsNitric Oxide Gas, The delivery system will be set up anyway without study gas administration
NCT05721144 phase2completednot on this mapstarted 2023, after this paper: background citation

Inhaled NO ReDuce postoperatIve pulmoNAry complicATions in patiEnts With Recent COVID-19 Infection

TypeinterventionalSponsorXijing HospitalRan2023 to 2024Enrolled660ConditionsNitric Oxide, COVID-19, Surgery, Postoperative ComplicationsArmsNitric Oxide Gas
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 126 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Current drug discovery technologies · 2024
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Wanyi FangNational 111 Center for Cellular Regulation and Molecular Pharmaceutics, Wuhan, Hubei, China; Department of Biomedicine and Biopharmacology, Hubei University of Technology, Wuhan, Hubei, China.
Jingrui JiangNational 111 Center for Cellular Regulation and Molecular Pharmaceutics, Wuhan, Hubei, China; Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Lei SuSchool of Biomedical Engineering, Shenzhen University, Shenzhen, Guangdong, China.
Tong ShuSchool of Biomedical Engineering, Shenzhen University, Shenzhen, Guangdong, China.
Huan LiuNational 111 Center for Cellular Regulation and Molecular Pharmaceutics, Wuhan, Hubei, China; Department of Biomedicine and Biopharmacology, Hubei University of Technology, Wuhan, Hubei, China.
Shenghan LaiJohns Hopkins University School of Medicine, Maryland, USA.
Reza A GhiladiDepartment of Chemistry, North Carolina State University, North Carolina, USA.
Jun WangNational 111 Center for Cellular Regulation and Molecular Pharmaceutics, Wuhan, Hubei, China; Department of Biomedicine and Biopharmacology, Hubei University of Technology, Wuhan, Hubei, China. Electronic address: jun_wang@hbut.edu.cn.
Hubei University of Technology · CNShenzhen University · CNHuazhong University of Science and Technology · CNJohns Hopkins University · USNorth Carolina State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nitric oxide (NO) is a free radical playing an important pathophysiological role in cardiovascular and immune systems. Recent studies reported that NO levels were significantly lower in patients with COVID-19, which was suggested to be closely related to vascular dysfunction and immune inflammation among them. In this review, we examine the potential role of NO during SARS-CoV-2 infection from the perspective of the unique physical, chemical and biological properties and potential mechanisms of NO in COVID-19, as well as possible therapeutic strategies using inhaled NO. We also discuss the limits of NO treatment, and the future application of this approach in prevention and therapy of COVID-19.

Indexed as

COVID-19 Drug TreatmentAdministration, InhalationAnticoagulantsAnti-Inflammatory AgentsAntiviral AgentsCOVID-19Endothelial CellsHumansInflammationLungMitochondriaNitric OxideSARS-CoV-2Severity of Illness IndexVasodilationAnticoagulantsAnti-Inflammatory AgentsAntiviral AgentsNitric OxideAnti-inflammationAnti-viralCOVID-19Nitric oxideVasodilation

Identifiers

PMID33347987
PMCPMC7754882
OpenAlexW3117241651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.